FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Realm US

18,400 resources

Type: Text:

By Version

By Authority

 

Start Prev Rows 11600 - 11800 Next

PackageVersionIdentityName/TitleStatusFMMWGDateAuth
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1078Canceractive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1079Canceractive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1080Chemotherapy Administrationactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1081Chemotherapy Administrationactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.111Ophthalmological Servicesactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.113Prostate Cancer Treatmentactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.118Initial Myocardial Infarctionactive2020-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.119Initial Myocardial Infarctionactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.120Coronary Artery Disease No MIactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1238Ejection Fractionactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1243Psychoanalysisactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1244Renal Failure Due to ACE Inhibitoractive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1251Group Psychotherapyactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1256Allergy to ACE Inhibitor or ARBactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1257Intolerance to ACE Inhibitor or ARBactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.133Beta Blocker Therapyactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1333Allergy to Beta Blocker Therapyactive2019-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1334Intolerance to Beta Blocker Therapyactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1341Heart Rateactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1342Beta Blocker Therapy for LVSDactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1344Acute and Subacute Iridocyclitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1353Limited Life Expectancyactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1363Annual Wellness Visitactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1364Macular Examactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1372Tobacco Use Screeningactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1374Bone Scanactive2018-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1377Level of Severity of Retinopathy Findingsactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1381Macular Edema Findings Presentactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1401Cognitive Assessmentactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1402Cup to Disc Ratioactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1403Optic Disc Exam for Structural Abnormalitiesactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1509Acute and Subacute Iridocyclitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1521Burn Confined to Eye and Adnexaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1523Burn Confined to Eye and Adnexaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1524Cataract Secondary to Ocular Disordersactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1526Cataract Secondary to Ocular Disordersactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1527Cataract Surgeryactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1528Cataract Surgeryactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1529Cataract Congenitalactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1530Cataract Congenitalactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1532Cataract Mature or Hypermatureactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1534Cataract Mature or Hypermatureactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1535Cataract Posterior Polaractive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1537Cataract Posterior Polaractive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1538Certain Types of Iridocyclitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1540Certain Types of Iridocyclitisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1542Chronic Iridocyclitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1543Chronic Iridocyclitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1544Cloudy Corneaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1546Cloudy Corneaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1548Corneal Edemaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1549Corneal Edemaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1550Disorders of Cornea Including Corneal Opacityactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1552Disorders of Cornea Including Corneal Opacityactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1561Glaucomaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1562Glaucomaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1564Hereditary Corneal Dystrophiesactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1566Hereditary Corneal Dystrophiesactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1571Hypotony of Eyeactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1572Hypotony of Eyeactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1574Injury to Optic Nerve and Pathwaysactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1575Injury to Optic Nerve and Pathwaysactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1577Central Corneal Ulceractive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1578Central Corneal Ulceractive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1582Open Wound of Eyeballactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1583Open Wound of Eyeballactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1587Pathologic Myopiaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1588Pathologic Myopiaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1590Posterior Lenticonusactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1591Posterior Lenticonusactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1601Retrolental Fibroplasiasactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1603Retrolental Fibroplasiasactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1612Traumatic Cataractactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1613Traumatic Cataractactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1615Uveitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1617Uveitisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1618Vascular Disorders of Iris and Ciliary Bodyactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1620Vascular Disorders of Iris and Ciliary Bodyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1621Visual Field Defectsactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1623Visual Field Defectsactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1626Amblyopiaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1628Amblyopiaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1632Choroidal Degenerationsactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1634Choroidal Degenerationsactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1635Choroidal Detachmentactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1637Choroidal Detachmentactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1638Choroidal Hemorrhage and Ruptureactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1640Choroidal Hemorrhage and Ruptureactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1641Degeneration of Macula and Posterior Poleactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1643Degeneration of Macula and Posterior Poleactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1644Degenerative Disorders of Globeactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1646Degenerative Disorders of Globeactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1647Diabetic Macular Edemaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1649Diabetic Macular Edemaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1653Disorders of Optic Chiasmactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1655Disorders of Optic Chiasmactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1656Disorders of Visual Cortexactive2021-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1658Disorders of Visual Cortexactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1659Disseminated Chorioretinitis and Disseminated Retinochoroiditisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1661Disseminated Chorioretinitis and Disseminated Retinochoroiditisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1662Focal Chorioretinitis and Focal Retinochoroiditisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1664Focal Chorioretinitis and Focal Retinochoroiditisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1665Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromesactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1667Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromesactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1668Hereditary Choroidal Dystrophiesactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1670Hereditary Choroidal Dystrophiesactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1671Hereditary Retinal Dystrophiesactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1673Hereditary Retinal Dystrophiesactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1677Nystagmus and Other Irregular Eye Movementsactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1679Nystagmus and Other Irregular Eye Movementsactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1680Optic Atrophyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1682Optic Atrophyactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1683Optic Neuritisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1685Optic Neuritisactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1686Other and Unspecified Forms of Chorioretinitis and Retinochoroiditisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1688Other and Unspecified Forms of Chorioretinitis and Retinochoroiditisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1689Other Background Retinopathy and Retinal Vascular Changesactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1691Other Background Retinopathy and Retinal Vascular Changesactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1695Other Disorders of Optic Nerveactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1697Other Disorders of Optic Nerveactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1701Other Endophthalmitisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1703Other Endophthalmitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1707Prior Penetrating Keratoplastyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1709Prior Penetrating Keratoplastyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1713Purulent Endophthalmitisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1715Purulent Endophthalmitisactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1716Retinal Detachment with Retinal Defectactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1718Retinal Detachment with Retinal Defectactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1719Retinal Vascular Occlusionactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1721Retinal Vascular Occlusionactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1722Other Proliferative Retinopathyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1724Other Proliferative Retinopathyactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1728Separation of Retinal Layersactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1730Separation of Retinal Layersactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1731Visual Acuity 20/40 or Betteractive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.175Hypotensionactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1752Speech and Hearing Evaluationactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.176Arrhythmiaactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1766Morgagnian Cataractactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1767Morgagnian Cataractactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1769Macular Scar of Posterior Polaractive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.177Atrioventricular Blockactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1770Macular Scar of Posterior Polaractive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1771Ophthalmological Servicesactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1772Annual Wellness Visitactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1773Speech and Hearing Evaluationactive2019-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1774Occupational Therapy Evaluationactive2021-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1775Behavioral Neuropsych Assessmentactive2019-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1776Psych Visit Diagnostic Evaluationactive2020-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1777Psych Visit Psychotherapyactive2019-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1778Psychoanalysisactive2019-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1779Group Psychotherapyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.178Cardiac Pacer in Situactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1780Psych Visit for Family Psychotherapyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1781Best Corrected Visual Acuity Exam Using Snellen Chartactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.180Hypotensionactive2023-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.181Arrhythmiaactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.183Cardiac Pacer in Situactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.185Hypotensionactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.186Arrhythmiaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.187Atrioventricular Blockactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1912Major Depressive Disorder Activeactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1918Major Depressive Disorder Activeactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1923Psych Visit Diagnostic Evaluationactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1924Cardiac Pacer in Situactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.408Bradycardiaactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.410Bradycardiaactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.411Bradycardiaactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.422Tobacco Useractive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.423Tobacco Use Cessation Pharmacotherapyactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.424Tobacco Use Cessation Counselingactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.425Tobacco Use Cessation Counselingactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.450Pain Warranting Further Investigation for Prostate Canceractive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.469Bilateral Oophorectomyactive2017-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.470Bilateral Oophorectomyactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.483Chemotherapyactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.484Chemotherapyactive2021-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.511Tobacco Non Useractive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.532Pregnancyactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.56Coronary Artery Disease No MIactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.57Coronary Artery Disease No MIactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.58Initial Myocardial Infarctionactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.589End Stage Renal Diseaseactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.59Asthmaactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.590End Stage Renal Diseaseactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.60Asthmaactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.61Asthmaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.73Primary Open Angle Glaucomaactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.74Primary Open Angle Glaucomaactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.76Diabetic Retinopathyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.80Diabetic Retinopathyactive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.859Left Ventricular Systolic Dysfunctionactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.860Moderate or Severeactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.861Moderate or Severe LVSDactive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.91Prostate Canceractive2017-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.92Prostate Canceractive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.3.1002Chronic Kidney Disease, Stage 5active2020-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.3.1005Dementia and Mental Degenerationsactive2020-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.3.1006Standardized Tools Score for Assessment of Cognitionactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.3.1007Medical Reasonactive2022-03hl7